Ronny I Drapkin

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc The new face of ovarian cancer modeling: better prospects for detection and treatment
    Alison M Karst
    Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute 450 Brookline Avenue, Boston, MA 02215 USA
    F1000 Med Rep 3:22. 2011
  2. pmc Ex vivo culture of primary human fallopian tube epithelial cells
    Susan Fotheringham
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Vis Exp . 2011
  3. pmc Ovarian cancer pathogenesis: a model in evolution
    Alison M Karst
    Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Oncol 2010:932371. 2010
  4. pmc Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
    K Levanon
    Department of Medical Oncology, Center of Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncogene 29:1103-13. 2010
  5. pmc Urokinase-type plasminogen activator receptor: a beacon of malignancy?
    Ronny Drapkin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 14:5643-5. 2008
  6. ncbi request reprint Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
    Ronny Drapkin
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:2162-9. 2005
  7. doi request reprint PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma
    Anna R Laury
    Department of Pathology Section, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 34:627-35. 2010
  8. pmc Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival
    Adam Clauss
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02115, USA
    Neoplasia 12:161-72. 2010
  9. ncbi request reprint Serous carcinogenesis in the fallopian tube: a descriptive classification
    Elke Jarboe
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:1-9. 2008
  10. pmc New insights into the pathogenesis of serous ovarian cancer and its clinical impact
    Keren Levanon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5284-93. 2008

Research Grants

Collaborators

  • Marisa R Nucci
  • J L Hecht
  • Yi Zhang
  • Christopher P Crum
  • M Meyerson
  • U A Matulonis
  • Elke Jarboe
  • Joyce F Liu
  • S C Mok
  • Alison M Karst
  • Qing Sheng
  • Keren Levanon
  • Susan Fotheringham
  • Anna R Laury
  • Huiying Piao
  • K Levanon
  • Adam Clauss
  • Michelle S Hirsch
  • Vivian Ng
  • David M Livingston
  • Arcangela De Nicolo
  • Koji Nozaki
  • Veerle Bossuyt
  • Daniel P Silver
  • Regina Groisman
  • Tomas Bonome
  • M S Hirsch
  • Seth Ettenberg
  • M C Chang
  • Roman K Thomas
  • William C Hahn
  • Zeinab Moustafa
  • Natalie Vena
  • Moises Russo
  • Andrew L Kung
  • Jinyun Chen
  • David Batt
  • Jason L Hornick
  • J A Marto
  • M H Roh
  • Xinggang Liu
  • Jeffrey F Krane
  • D W Kindelberger
  • Ruth Perets
  • V Ng
  • Michael J Birrer
  • Karen Yuan
  • H Y Piao
  • Sara Zaghlul
  • Azra H Ligon
  • Anna Schinzel
  • Birgit Schoeberl
  • Eleanor Fleming
  • Heidi Greulich
  • Joseph Corson
  • James R Goldenring
  • Fabiola Medeiros
  • Stephen F Konieczny
  • Mariella Tancredi
  • Cristina Chantal Flemma
  • Jason C Mills
  • Bonnie J Lafleur
  • Sachiyo Nomura
  • Bijan Sobhian
  • Ann K Folkins
  • Grazia Lombardi
  • Janice A Williams
  • Serena Barbuti
  • Maria Adelaide Caligo
  • Masako Ogawa
  • Generoso Bevilacqua
  • Claudio Di Cristofano
  • Shihua D Lu
  • Soundarapandian Velmurugan
  • Elena Shestakova
  • Sven Rottenberg
  • Shridar Ganesan
  • Jessica Mar
  • Xiaoling Liu
  • Jos Jonkers
  • Nicholas Denunzio
  • Jean Feunteun
  • Stoil D Dimitrov
  • Serban Dragomir
  • Rebecca Gelman
  • Jolanta Polanowska
  • Masafumi Saijo
  • Jun Ichi Sawada
  • Kiyoji Tanaka
  • Alexei F Kisselev

Detail Information

Publications21

  1. pmc The new face of ovarian cancer modeling: better prospects for detection and treatment
    Alison M Karst
    Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute 450 Brookline Avenue, Boston, MA 02215 USA
    F1000 Med Rep 3:22. 2011
    ..In doing so, we can hopefully improve early detection, treatment, and outcome...
  2. pmc Ex vivo culture of primary human fallopian tube epithelial cells
    Susan Fotheringham
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Vis Exp . 2011
    ..This ex vivo model provides a useful tool for the study of SOC, allowing a better understanding of how tumors can arise from this tissue, and the mechanisms involved in tumor initiation and progression...
  3. pmc Ovarian cancer pathogenesis: a model in evolution
    Alison M Karst
    Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Oncol 2010:932371. 2010
    ..The ovarian cancer model will continue to evolve as we learn more about the genetics and etiology of this disease...
  4. pmc Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
    K Levanon
    Department of Medical Oncology, Center of Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncogene 29:1103-13. 2010
    ..We anticipate that this novel culture system will facilitate the study of SOC pathogenesis, and propose that similar culture systems could be developed for other organ site-specific epithelia...
  5. pmc Urokinase-type plasminogen activator receptor: a beacon of malignancy?
    Ronny Drapkin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 14:5643-5. 2008
    ..Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies...
  6. ncbi request reprint Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
    Ronny Drapkin
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:2162-9. 2005
    ..Its expression in cortical inclusion cysts suggests that formation of Mullerian epithelium is a prerequisite step in the development of some types of EOCs...
  7. doi request reprint PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma
    Anna R Laury
    Department of Pathology Section, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 34:627-35. 2010
    ..The presence of weak staining for PAX8 in the 3 "noninvasive" mesotheliomas questions the use for PAX8 in this differential diagnosis. On the basis of this study, h-caldesmon is not a useful marker for mesothelioma...
  8. pmc Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival
    Adam Clauss
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02115, USA
    Neoplasia 12:161-72. 2010
    ..These results, combined with our observation that Elafin is secreted by ovarian tumors and is minimally expressed in normal tissues, suggest that Elafin may serve as a determinant of poor survival in this disease...
  9. ncbi request reprint Serous carcinogenesis in the fallopian tube: a descriptive classification
    Elke Jarboe
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:1-9. 2008
    ..Combined with recent reports associating STICs with pelvic serous cancer, this continuum of epithelial change validates the SCAT sequence and the fimbrial secretory cell as the site of origin for many serous carcinomas...
  10. pmc New insights into the pathogenesis of serous ovarian cancer and its clinical impact
    Keren Levanon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5284-93. 2008
    ..With the rise of the fallopian tube secretory epithelial cell as a cell of origin for high-grade pelvic serous carcinomas, the need to develop tools and model systems to characterize the biology and physiology of this cell is recognized...
  11. ncbi request reprint Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia
    Ronny Drapkin
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Hum Pathol 35:1014-21. 2004
    ..This immunophenotype is preserved in ovarian carcinomas, suggesting that Müllerian metaplasia signals the acquisition of these markers and that their expression is maintained in ovarian carcinomas that originate from this epithelium...
  12. pmc An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells
    Qing Sheng
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 17:298-310. 2010
    ..Furthermore, a monoclonal ErbB3-directed antibody (MM-121) also significantly inhibited tumor growth in vivo. These findings identify ErbB3 as a potential therapeutic target in ovarian cancer...
  13. pmc A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function
    Arcangela De Nicolo
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 14:4672-80. 2008
    ..We aimed to assess whether BRIP1 mutations contribute to breast cancer susceptibility in our population and, if so, to investigate the effect of such mutation(s) on BRIP1 function...
  14. doi request reprint Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma
    Veerle Bossuyt
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:390-7. 2008
    ..Whether the shared tumor phenotype in these 2 organs is coincidental or interdependent bears further investigation...
  15. ncbi request reprint Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications
    Marisa R Nucci
    Department of Pathology, Divisions of Women s and Perinatal Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 31:737-43. 2007
    ....
  16. pmc Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer
    Christopher P Crum
    Department of Pathology, Brigham and Womens Hospital, 75 Francis Street, Boston, MA 02115, USA
    Clin Med Res 5:35-44. 2007
    ....
  17. ncbi request reprint Further evidence for BRCA1 communication with the inactive X chromosome
    Daniel P Silver
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cell 128:991-1002. 2007
    ..Here we discuss recently published data from our laboratory and others and present new results that, together, provide further support for a role of BRCA1 in the regulation of XIST concentration on Xi in somatic cells...
  18. ncbi request reprint The distal fallopian tube: a new model for pelvic serous carcinogenesis
    Christopher P Crum
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Curr Opin Obstet Gynecol 19:3-9. 2007
    ....
  19. ncbi request reprint The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage
    Regina Groisman
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cell 113:357-67. 2003
    ..Knockdown of CSN with RNA interference leads to defects in NER. These results suggest that the distinct UV response of the DDB2 and CSA complexes is involved in diverse mechanisms of NER...
  20. pmc A molecular signature of gastric metaplasia arising in response to acute parietal cell loss
    Koji Nozaki
    Nashville VA Medical Center and the Department of Surgery, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Gastroenterology 134:511-22. 2008
    ..We now sought to characterize more definitively the pathway for emergence of SPEM...

Research Grants2

  1. BACH1 Function in DNA Repair and Mammary Oncogenesis
    Ronny Drapkin; Fiscal Year: 2007
    ..The sponsor, Dr. David Livingston, is a recognized world-leader in cancer biology with a strong record of training successful basic investigators. ..